The cost of treating hypertension in Australia, 2012–22: an economic analysis
During 2012-22, about 40% of the cost of managing hypertension in Australia was borne directly by patients (about $494 million per year). Important changes to pharmacy supply and payment policies were introduced in 2023, but further efforts may be needed to reduce treatment costs for patients. These changes are particularly important if the hypertension control rate is to be substantially improved in Australia, given the large numbers of undertreated and untreated people with hypertension.
Authors
- Emily Atkins (ORCID: https://orcid.org/0000-0003-2522-3510)
- Anthony Rodgers (ORCID: https://orcid.org/0000-0003-1282-1896)
- Markus Peter Schlaich (ORCID: https://orcid.org/0000-0002-1765-0195)
- Mary Lou Chatterton (ORCID: https://orcid.org/0000-0003-4902-9448)
- Long Nguyen (ORCID: https://orcid.org/0000-0003-1931-9284)
- Aletta Elisabeth Schutte (ORCID: https://orcid.org/0000-0001-9217-4937)
Institutions
- The University of Melbourne (AU)
- The University of Western Australia (AU)
- UNSW Sydney (AU)
- Monash University (AU)
Publication Details
- Journal
- The Medical Journal of Australia
- Published
- 2024-11-24
- DOI
- https://doi.org/10.5694/mja2.52522
- Citations
- 4
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Pfizer
- Servier
- National Health and Medical Research Council